镰状细胞病中脾危象的急性发作:190 例儿科患者的队列研究。
Acute splenic sequestration crisis in sickle cell disease: cohort study of 190 paediatric patients.
机构信息
Department of Paediatrics, Reference Centre for Sickle Cell Disease, Hôpital Necker, APHP, Paris, France.
出版信息
Br J Haematol. 2012 Mar;156(5):643-8. doi: 10.1111/j.1365-2141.2011.08999.x. Epub 2012 Jan 9.
Acute splenic sequestration crisis (ASSC) is an unpredictable life-threatening complication of sickle cell disease (SCD) in infants. Here, our objective was to update available clinical information on ASSC. We retrospectively studied the 190 patients who were diagnosed at birth with SS or Sbeta(0) in the Paris conurbation between 2000 and 2009 and who experienced ASSC. They had 437 ASSC episodes (0.06/patient-year). Median age at the first episode was 1.4 years (0.1-7) and 67% of patients had more than one episode. Age was the only factor predicting recurrence: the risk was lower when the first episode occurred after 2 years versus before 1 year of age (hazard ratio, 0.60; 95% confidence interval, 0.41-0.88; P=0.025). A concomitant clinical event was found in 57% of episodes. The mortality rate was 0.53%. The treatment consisted in watchful waiting without prophylactic blood transfusions or splenectomy in 103 (54%) patients and in a blood transfusion programme in 55 (29%) patients. Overall, splenectomy was performed in 71 (37%) patients, at a median age of 4.5 years (range, 1.9-9.4). In conclusion, aggressive treatment may be warranted in patients experiencing ASSC before 2 years of age. Randomized controlled trials are needed to define the best treatment modalities.
急性脾危象(ASSC)是镰状细胞病(SCD)婴儿中一种不可预测的危及生命的并发症。在这里,我们旨在更新 ASSC 的现有临床信息。我们回顾性研究了 190 名在 2000 年至 2009 年期间在巴黎市区出生时被诊断为 SS 或 Sβ(0)的患者,并经历了 ASSC。他们共有 437 次 ASSC 发作(0.06/患者年)。首次发作的中位年龄为 1.4 岁(0.1-7),67%的患者有多次发作。年龄是预测复发的唯一因素:首次发作发生在 2 岁以后的风险低于 1 岁以前(风险比,0.60;95%置信区间,0.41-0.88;P=0.025)。57%的发作伴有伴随的临床事件。死亡率为 0.53%。治疗方法包括在 103 名(54%)患者中不进行预防性输血或脾切除术的观察等待和在 55 名(29%)患者中进行输血方案。总体而言,71 名(37%)患者进行了脾切除术,中位年龄为 4.5 岁(范围 1.9-9.4)。总之,在 2 岁之前经历 ASSC 的患者可能需要积极治疗。需要进行随机对照试验来确定最佳治疗方式。